#OP0127 A post-hoc analysis of two RCTs showed that continued methotrexate increases clinical response rates in patients randomized to placebo therapy who were considered as having previous insufficient response to #bDMARDs. #EULAR2021 @RheumNow https://t.co/YeEVe0uwQs